ZILXI

PeakSM

minocycline

NDATOPICALAEROSOL, FOAM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
11

Clinical Trials (5)

NCT03762915Phase 4Completed

Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg

Started May 2019
NCT02187211Phase 1Completed

Minocycline's Effects on Alcohol Responses in Humans

Started Jul 2015
54 enrolled
Alcohol Dependence
NCT02297412Phase 2Completed

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Started Nov 2014
47 enrolled
Acute PainBreast CarcinomaPeripheral Neuropathy
NCT01809340Phase 2Terminated

The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression

Started Jun 2013
29 enrolled
Depressive Disorder
NCT01938508Phase 1Completed

Minocycline Bioequivalence Study

Started May 2013
28 enrolled
Skin Diseases

Loss of Exclusivity

LOE Date
Oct 1, 2030
55 months away
Patent Expiry
Oct 1, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
10213512
Oct 1, 2030
Product
U-1631
10265404
Oct 1, 2030
Product
10322186
Oct 1, 2030
U-1631
10946101
Oct 1, 2030
U-1631
12138311
Oct 1, 2030
U-1631